C1

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, May 10, 2023
Phibro, RBD, Marketing, Public, Enzyme, Biomedical Advanced Research and Development Authority, Fungus, Influenza, Science, Development, Pandemic, Protein, COVID-19 vaccine, Patent, WNV, Rubic Ghasemi-Nobakht, TBEV, Antigen, University of California, Davis, Albumin, Therapy, Fermentation, Research, Infection, Gene expression, Consultant, RVFV, CGMP, Manuscript, Recombinant, Growth, FDA, BARDA, ACE2, Safety, D, Vaccine, DNA, COVID-19, Antibody, CSR, Government, Animal, UC, Webcast, Food, Omicron, Education, SARS-CoV-2, Clinical trial, CHO, Sale, NIIMBL, Health, Pharmaceutical industry, Financial adviser, Cryptocurrency, Fine chemical, Rare-earth element, Video game, EU, African, C1, Dyadic

Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.

Key Points: 
  • Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.
  • In the first quarter of 2023, the Company entered into a new research collaboration with a biotech company for a fully funded proof-of-concept project to express an enzyme for pharmaceutical applications.
  • G&A Expenses: General and administrative expenses for the quarter ended March 31, 2023, decreased by 10.6% to approximately $1,480,000 compared to $1,656,000 for the quarter ended March 31, 2022.
  • Other Income: Other income for the quarter ended March 31, 2023 was from the sale of the equity interest in Alphazyme, LLC.

Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™

Retrieved on: 
Monday, May 8, 2023
C1, Food, Subbu, Fermentation, Marketing, Fine chemical, Dyadic

Under the agreement, Dyadic and Fermbox expect to use Dyadic’s proprietary Dapibus™ filamentous fungal based microbial protein production platform and Fermbox’s extensive product development capabilities, to design, develop and commercialize innovative animal free alternative proteins and biomaterials.

Key Points: 
  • Under the agreement, Dyadic and Fermbox expect to use Dyadic’s proprietary Dapibus™ filamentous fungal based microbial protein production platform and Fermbox’s extensive product development capabilities, to design, develop and commercialize innovative animal free alternative proteins and biomaterials.
  • “Fermbox has extensive expertise in bio-alternate development and microbial precision fermentation which we expect will accelerate our ability to exploit the DapibusTM platform and expand Dyadic’s product offerings for non-pharmaceutical alternative proteins applications, such as food, nutrition, wellness and other bioproducts.
  • We anticipate this collaboration will enhance our market penetration into the alternative protein markets at the same time our biopharmaceutical activities using C1 are also advancing at a rapid pace.
  • Our joint expertise across expression systems and execution capabilities from lab to large scale manufacturing, uniquely positions us for success.

Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

Retrieved on: 
Tuesday, April 18, 2023
Vaccine, Patent, Antigen, Human, Diabetes, Arthritis, Infection, Research, COVID, Antibody, Fungus, DSM-IV codes, Invention, Conference, C1, Dyadic

The Patent will cover claims for the development and manufacture of seasonal and pandemic influenza vaccines from the Company’s C1 protein production platform.

Key Points: 
  • The Patent will cover claims for the development and manufacture of seasonal and pandemic influenza vaccines from the Company’s C1 protein production platform.
  • The human influenza vaccine market is currently valued at approximately $8 Billion USD and expected to grow to over $12 by 2028 with multi-valent vaccines leading the market.
  • “Data presented at the World Vaccine Conference earlier this month demonstrated the capability of C1 to produce flu and other antigens.
  • We believe C1 has the potential to become a global solution for seasonal or pandemic rapid production, at affordable costs for developed and emerging countries, and for mono or multi-valent vaccines,” continued Mr. Emalfarb.

iFLYTEK Facilitates Barrier-free Communication for Participants at the 10th International Abilympics

Retrieved on: 
Monday, April 17, 2023
Communication, International, Olympic Games, Disability, C1, China Disabled Persons' Federation, Silver, Metz, Human voice, Gold, HarmonyOS, Reading, APP, AI, Mobile phone, Cassette tape

HEFEI, China, April 17, 2023 /PRNewswire/ -- The 10th International Abilympics—the top global skills competition for those with disabilities—in Metz, France recently concluded.

Key Points: 
  • HEFEI, China, April 17, 2023 /PRNewswire/ -- The 10th International Abilympics—the top global skills competition for those with disabilities—in Metz, France recently concluded.
  • iFLYTEK is committed to facilitating barrier-free communication worldwide and has jointly launched the public welfare program, "Hear the Voice of AI", with the China Disabled Persons' Federation.
  • At the competition, iFLYTEK enabled barrier-free international communication through its donation of products iFLYREC APP, the iFLYTEK Translator, the iFLYTEK Smart Wireless Microphone C1, the iFLYTEK Smart Omnidirectional Microphone M2, and the iFLYREC Document Translation, among others.
  • Participants of the games with disabilities used the iFLYTEK Translator for voice translation and communication.

Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent

Retrieved on: 
Wednesday, April 12, 2023
Vaccine, Partnership, Drug development, RBD, C1, COVID-19, Temperature, Rubic Ghasemi-Nobakht, Health, Pharmaceutical industry, African, Dyadic

We’ve since progressed to the ongoing Phase 1 first in human trial for the DYAI-100 recombinant RBD booster vaccine candidate for COVID-19, which has facilitated the expansion of our licensing agreement with Rubic.

Key Points: 
  • We’ve since progressed to the ongoing Phase 1 first in human trial for the DYAI-100 recombinant RBD booster vaccine candidate for COVID-19, which has facilitated the expansion of our licensing agreement with Rubic.
  • The expanded agreement provides Rubic with the ability to broaden its potential to commercialize both human and animal health products for Africa using our C1 technology.
  • “It is imperative that African nations acquire and commercialize technology and manufacturing capabilities necessary to deploy preventative and therapeutic treatments for broad populations, both affordably and timely.
  • This agreement will help Rubic achieve its strategic goal of providing an end-to-end solution for vaccine and drug development, production, and distribution, for the African continent,” concluded Dr. Julian Naidoo.

Innokin Partnered Aquios with Water-Based Vaping to Make a Splash in 2023

Retrieved on: 
Thursday, March 9, 2023
Smoking, Herbal cigarette, FMCG, Golden LEAF Biomanufacturing Training and Education Center, C1, Acetaldehyde, Water, Dehydration, Formaldehyde, Nicotine, Research, Smoker, Tobacco

The high water content was made possible through a specialised formulation process developed by Aquios Labs and a new hardware design developed by Innokin.

Key Points: 
  • The high water content was made possible through a specialised formulation process developed by Aquios Labs and a new hardware design developed by Innokin.
  • Research and development took more than 2 years, and the resulting technology is a unique offering in the vaping market.
  • The initial line-up of water-based vaping products was launched in all major markets in the first quarter of 2022, including Aquios Bar and Esco bar 6000.
  • With water-based vaping technology on track to gain a significant share of the market in 2023, Innokin and Aquios Labs aim to launch the products in more markets over the coming year.

Innokin Partnered Aquios with Water-Based Vaping to Make a Splash in 2023

Retrieved on: 
Thursday, March 9, 2023
Smoking, Herbal cigarette, FMCG, Golden LEAF Biomanufacturing Training and Education Center, C1, Acetaldehyde, Water, Dehydration, Formaldehyde, Nicotine, Research, Smoker, Tobacco

The high water content was made possible through a specialised formulation process developed by Aquios Labs and a new hardware design developed by Innokin.

Key Points: 
  • The high water content was made possible through a specialised formulation process developed by Aquios Labs and a new hardware design developed by Innokin.
  • Research and development took more than 2 years, and the resulting technology is a unique offering in the vaping market.
  • The initial line-up of water-based vaping products was launched in all major markets in the first quarter of 2022, including Aquios Bar and Esco bar 6000.
  • With water-based vaping technology on track to gain a significant share of the market in 2023, Innokin and Aquios Labs aim to launch the products in more markets over the coming year.

Hollyland Unveils Solidcom C1 Pro, World's First Wireless Dual-Mic ENC Intercom Headset System

Retrieved on: 
Thursday, March 9, 2023
Communication, Magic, C1, PTT, DECT, ENC, Mobile phone

The Solidcom C1 Pro is a true game changer with built-in ENC technology. Just activate the ENC switch and unleash the magic. Each headset has TWO mics -- the unidirectional main mic captures the speaker's voice range and simultaneously, the omnidirectional secondary mic records the 360° background noise levels. Through a process with the advanced ENC algorithm, the background noise is able to be eliminated by up to 20dB, which ensures your crew a crystal clear sound during team talk. To test the practical use, Hollyland invited over 10 church teams to experience the Solidcom C1 Pro for 2 months and has received great feedback from them. Feel free to review the case study: Awaken Church x Hollyland. 

Key Points: 
  • SHENZHEN, China, March 8, 2023 /PRNewswire/ -- Hollyland, the leading wireless solution provider, has announced Solidcom C1 Pro , the first full-duplex wireless dual-mic Environmental Noise Cancellation (ENC) intercom system.
  • As an upgrade over its predecessor, Solidcom C1 Pro offers a groundbreaking team communication experience with the ENC technology and Push-to-Talk (PTT) function.
  • More importantly, the Pro version is entirely compatible with Solidcom C1 , which means users may add the Pro headsets to the existing C1 system for the enhancing on-site intercom experience.
  • 10-hour Remote Headset Operation Time, 6-hour Master Headset Operation Time (with 3 Remote Headsets)
    "The 2022 Solidcom C1 sets a new benchmark for the wireless intercom market and quickly becomes the category top seller.

Hollyland Unveils Solidcom C1 Pro, World's First Wireless Dual-Mic ENC Intercom Headset System

Retrieved on: 
Thursday, March 9, 2023
Communication, Magic, C1, PTT, DECT, ENC, Mobile phone

The Solidcom C1 Pro is a true game changer with built-in ENC technology. Just activate the ENC switch and unleash the magic. Each headset has TWO mics -- the unidirectional main mic captures the speaker's voice range and simultaneously, the omnidirectional secondary mic records the 360° background noise levels. Through a process with the advanced ENC algorithm, the background noise is able to be eliminated by up to 20dB, which ensures your crew a crystal clear sound during team talk. To test the practical use, Hollyland invited over 10 church teams to experience the Solidcom C1 Pro for 2 months and has received great feedback from them. Feel free to review the case study: Awaken Church x Hollyland.

Key Points: 
  • SHENZHEN, China, March 9, 2023 /PRNewswire/ -- Hollyland, the leading wireless solution provider, has announced Solidcom C1 Pro , the first full-duplex wireless dual-mic Environmental Noise Cancellation (ENC) intercom system.
  • As an upgrade over its predecessor, Solidcom C1 Pro offers a groundbreaking team communication experience with the ENC technology and Push-to-Talk (PTT) function.
  • More importantly, the Pro version is entirely compatible with Solidcom C1 , which means users may add the Pro headsets to the existing C1 system for the enhancing on-site intercom experience.
  • 10-hour Remote Headset Operation Time, 6-hour Master Headset Operation Time (with 3 Remote Headsets)
    "The 2022 Solidcom C1 sets a new benchmark for the wireless intercom market and quickly becomes the category top seller.

Mineração Vale Verde reports 2022 performance and completion of operational ramp-up

Retrieved on: 
Wednesday, February 22, 2023
Life, Woman, Biophysical environment, Water, Safety, Nolde Forest Environmental Education Center, Mathematics, EBITDA, Seed, Health, Seedling, School, ESG, Student, GHG, MVV, Social, Educando a Nina (Mexican TV series), Caboclo, Education, Growth, LTI, EEC, Municipality, VFL, Mine, STEM, Social media, Poultry, Total Recordable Incident Rate, Collection, Cryptocurrency, Copper, Airline, Mining, Q4, Caatinga, C1

Having completed construction within schedule and below budget we successfully ramped up to deliver a strong operational and financial performance.

Key Points: 
  • Having completed construction within schedule and below budget we successfully ramped up to deliver a strong operational and financial performance.
  • MVV has delivered Serrote with an industry-leading safety record, with zero (0) Lost Time Injuries ("LTI") in 1.9 million cumulative hours worked during 2022.
  • MVV delivered a strong operational performance in 2022, driven by its expert team and continuous business improvements strategy.
  • Updated technical reports are underway to confirm Mineração Vale Verde's growth to maintain the operations sustainability well above the initial 14 year life of mine.